Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584161 | 0.82 | HSD17B10 (0.50) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL14157279 | 0.79 | TTR (0.61) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL7050401 | 0.78 | MAOA (0.61) | ALDH1A1CYP3A4TDP1VCAM1MAOA | |
| SCHEMBL31441456 | 0.78 | MAOA (0.61) | ALDH1A1CYP3A4TDP1VCAM1MAOA | |
| SCHEMBL8333206 | 0.77 | HSD17B10 (0.50) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL11193415 | 0.77 | TTR (0.53) | HPGDHSP90AA1LMNAMAPTHSPA5 | |
| SCHEMBL101711 | 0.76 | TRPV4 (0.61) | HSD17B10CYP3A4TSHRTDP1VCAM1 | |
| SCHEMBL1267080 | 0.76 | ESR2 (0.44) | ESR1ESR2AR | |
| SCHEMBL3027689 | 0.74 | CA12 (0.48) | ALDH1A1CYP2A6MEN1KMT2ATTR | |
| SCHEMBL166558 | 0.73 | TSHR (0.52) | HSD17B10ALDH1A1CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12457898-B2 | Organic compound, composition, organic optoelectronic device, and display device | SAMSUNG SDI CO., LTD. (KR) | 2025-10-28 | — | — | US | disclosed |
| US-20250250237-A1 | ALKYLAMINE OR HETEROALKYLAMINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| CN-115572252-B | Isoindolinone inhibitors of MDM2-P53 interaction with anticancer activity | 阿斯泰克斯治疗有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024175905-A1 | DIMER COMPOUNDS | Kesmalea Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2024-08-27 | — | — | US | disclosed |
| CN-118451066-A | 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure | 辉瑞大药厂 | 2024-08-06 | — | — | CN | disclosed |
| CN-118119625-A | Pyrimidine-2 (1H) -keto bicyclic compounds with MAT2A inhibitory activity and application thereof | 上海海和药物研究开发股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-114773302-B | Benzofuran derivative and medical application thereof | 中国药科大学 | 2024-04-02 | — | — | CN | disclosed |
| US-5221674-A | Hypotensive agents having beta-blocking and vasodilation activity | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1993-06-22 | — | — | US | disclosed |
| US-5130314-A | Hypotensive agents | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1992-07-14 | — | — | US | disclosed |
| CN-1060467-A | 1,3-benzoxazine derivatives, its production method and purposes | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1992-04-22 | — | — | CN | disclosed |
| EP-0477789-A1 | 1,3-Benzoxazine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-04-01 | — | — | EP | disclosed |
| US-5082844-A | Hypotensive | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1992-01-21 | — | — | US | disclosed |
| EP-0259835-B1 | PYRIDAZINONE DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| EP-0413257-A2 | Cyclic poly(aryl ether) oligomers, a process for preparation thereof, and polymerization of cyclic poly (aryl ether) oligomers | THE DOW CHEMICAL COMPANY (US) | 1991-02-20 | — | — | EP | disclosed |
| EP-0404050-A1 | Pyridazinone derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1990-12-27 | — | — | EP | disclosed |
| US-4843072-A | Antihypertensive pyridazinone aminoisopropanol derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0259835-A2 | Pyridazinone derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | HSD17B10 32/4885ALDH1A1 468/4885CYP3A4 720/4885 |
| US-20250250237-A1 | ALKYLAMINE OR HETEROALKYLAMINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS3, NOS2, NOS1 | HSD17B10 1007/4885ALDH1A1 2486/4885CYP3A4 53/4885 |
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | HSD17B10 1960/4885ALDH1A1 1400/4885CYP3A4 1227/4885 |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | HSD17B10 1865/4885ALDH1A1 1361/4885CYP3A4 1087/4885 |
| US-12457898-B2 | Organic compound, composition, organic optoelectronic device, and display device | OXER1, OR10J3, OCIAD1 | HSD17B10 2232/4885ALDH1A1 91/4885CYP3A4 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.